Release Date: July 08, 2026
Source: QbD Pharmaceutical (Cangzhou) Co., Ltd.
Our in-house R&D team has recently completed systematic optimization of the full synthetic process for Theobromine API (CAS No. 83-67-0). With self-developed green synthetic routes, we drastically cut mass production costs while maintaining premium product quality. Our supply pricing now outperforms all manufacturers based in China and India across the entire industrial chain, delivering cost-effective and fully compliant raw material solutions for global pharmaceutical manufacturers and medical importers.
Led by our senior team of synthetic scientists, this technical upgrade addresses long-standing industry bottlenecks of conventional synthesis routes, including excessive by-products, high raw material loss and lengthy purification procedures. We reconstructed the catalytic reaction system and streamlined multi-stage refining workflows, alongside revamping continuous closed-loop production equipment. Three core competitive strengths are fully realized:
-
Unrivaled Global Price Competitiveness
Verified through multiple rounds of industrial mass production, the new process greatly improves overall yield and cuts consumption of raw materials, auxiliary chemicals and energy, slashing comprehensive manufacturing costs. Compared with mainstream Theobromine API suppliers in China and India, our spot supply prices carry prominent advantages. Tiered discounts are available for large-volume annual framework orders, perfectly matching long-term bulk procurement demands of manufacturers producing diuretics, cardiotonics and smooth muscle relaxants.
-
Consistent High Purity Above 99.0%
The upgraded refining process accurately controls critical impurity limits including related substances, heavy metals and residual solvents. HPLC assay confirms product purity stably maintained at ≥99.0%, fully complying with CP / BP / EP / USP pharmacopoeia standards. The finished product is uniform white crystalline powder with controllable crystal form and excellent flowability without caking risks, suitable for manufacturing sterile injectables and oral solid preparations. Each batch is accompanied by a full Certificate of Analysis (COA), and the whole production line operates under GMP quality management system, passing on-site audits from overseas pharmaceutical factories.
-
Complete Full-set DMF Dossier to Accelerate Global Registration
We have compiled and archived full Type II DMF (Drug Master File) technical documents for Theobromine, covering synthetic process, impurity profiling, analytical method validation, stability studies, GMP quality control records and toxicology safety data. The complete dossier can be submitted directly to clients across Europe, America, Central Asia, Southeast Asia and CIS countries for drug formulation registration, regulatory filing and import license application, significantly shortening overseas registration timelines and enabling partners to quickly obtain local marketing authorization.
As a classic xanthine pharmaceutical raw material, Theobromine is widely used in cardiovascular and urinary prescription drugs, with rising global procurement demand year by year. Restricted by raw material expenses, environmental regulations and outdated synthesis technology, most manufacturers struggle to balance low cost and high purity, a widespread pain point in the sector. Our latest process innovation resolves the industry trade-off between low price and premium quality. We also provide standardized 25kg fiber drum packaging with inner PE liner, constant-temperature professional pharmaceutical warehousing and global door-to-door logistics support. Sample testing and bulk purchase cooperation are open for pharmaceutical importers in Azerbaijan, Central Asia, the Middle East, Southeast Asia and other regions.
Moving forward, our R&D center will continue to advance process iteration for the xanthine API series. Supported by our independent research laboratory and Class 100,000-grade GMP manufacturing plant, we will consistently deliver cost-effective, highly compliant APIs, ensuring stable, low-cost and registration-ready raw material supply chains for the global pharmaceutical industry.
